THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FORTHE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
LONDON, Sept. 25, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that at the annual general meeting (the "Annual General Meeting") held earlier today the proposed resolutions set out in the notice of Annual General Meeting dated 9 September 2020 were duly passed.
The results of the proxy voting will be available shortly on the Company's website, https://www.okyopharma.com/news/.
The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO.
About OKYO
OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
Enquiries:
| OKYO Pharma Limited | Willy Simon | +44 (0)20 7382 8300 |
| Optiva Securities Limited | Robert Emmet | +44 (0)20 3981 4173 |
For further information, please visit the Company's website at www.okyopharma.com.
